Trials / NCT02556736
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Optogenetics, Gene therapy
- Sponsor
- AbbVie
- Treatment
- AGN-151597
- Gene
- Not gene-specific
- Conditions
- Advanced Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 14 participants
- Started
- 2015-12-14
- Main results expected
- 2020-06-01
- Results posted
- Yes
- Record last updated
- 2026-01-12
What the study is testing
All participants in phase 1 and phase 2a had hand motion visual acuity or worse.
If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Where it runs
United States (4)
- University of California San Francisco - Mission Bay /ID# 235717, San Francisco, California
- Cincinnati Eye Institute- Edgewood /ID# 236713, Edgewood, Kentucky
- Duke Eye Center /ID# 235715, Durham, North Carolina
- Retina Foundation of the Southwest /ID# 235199, Dallas, Texas